<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708353</url>
  </required_header>
  <id_info>
    <org_study_id>19-11-2020</org_study_id>
    <nct_id>NCT04708353</nct_id>
  </id_info>
  <brief_title>Oral Pregabalin Premedication for Postoperative Pain Relief</brief_title>
  <official_title>Effect of Two Different Doses of Oral Pregabalin Premedication for Postoperative Pain Relief After Gynecological Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain management after gynecological surgeries is essential for early mobilization of the&#xD;
      patient, decrease postoperative complication and hospital stay. The use of opioids is&#xD;
      associated with adverse effects such as nausea, vomiting, ileus, pruritus, sedation and&#xD;
      respiratory depression.&#xD;
&#xD;
      Previous studies stated that pregabalin has been used to reduce pre-operative anxiety, acute&#xD;
      postoperative pain, postoperative opioid requirements, postoperative nausea, vomiting and&#xD;
      postoperative delirium. The most effective dose of pregabalin to relief postoperative pain&#xD;
      with least side effect is still under trial.&#xD;
&#xD;
      In this study we will compare between two different doses of pregabalin when given as oral&#xD;
      premedication in patients undergoing gynecological surgeries under spinal anesthesia&#xD;
      regarding postoperative pain in order to reduce opioids consumption and subsequently avoid&#xD;
      opioid-related adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain, nausea and vomiting continue to be one of the most common and unpleasant&#xD;
      complications after surgery. The traditional pain treatment with opioids alone is not&#xD;
      adequate any more. To optimize pain treatment and postoperative outcome, new analgesics and&#xD;
      new combination of already existing analgesics are searched for.&#xD;
&#xD;
      Pain after gynecological surgery usually severe. Uncontrolled acute post-operative pain is&#xD;
      associated with dissatisfaction, post-operative complications and considered as a strong risk&#xD;
      factor for development of chronic pain. An enhanced recovery pathway for gynecological&#xD;
      surgery must include a strategy to effectively control post-operative pain and allow&#xD;
      attainment of other Enhanced Recovery After Surgery (ERAS) targets such as early mobilization&#xD;
      and return to oral diet whilst reducing the need for opiates.&#xD;
&#xD;
      Beyond increasing the risk of developing opioid use disorder, perioperative opioid&#xD;
      consumption may produce undesirable side effects such as nausea, vomiting, constipation,&#xD;
      ileus, pruritus, altered mental status, urinary retention, respiratory complications and&#xD;
      increased length of hospital stay. While many of these side effects are frustrating to&#xD;
      patient in the immediate postoperative period, the most dangerous effects are those that&#xD;
      affect the respiratory system such as opioid-induced respiratory depression (ORD) which&#xD;
      consider as a significant cause of brain damage and death in the postoperative period.&#xD;
&#xD;
      Opioid reduction strategies prove useful for decreasing total opioid dose and, in turn, their&#xD;
      associated adverse effects. Such strategies may include adjuvant non opioid analgesics such&#xD;
      as α-2 agonists, gabapentinoids and N-methyl-D-aspartate receptor agonists as well as local,&#xD;
      regional or neuraxial anesthesia and modification of surgical technique where possible for&#xD;
      operative patients.&#xD;
&#xD;
      Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory&#xD;
      neurotransmitter gamma-amino butyric acid. It is a α2-δ ligand that has analgesic,&#xD;
      anticonvulsant, anxiolytic and sleep-modulating activities. Pregabalin binds potently to the&#xD;
      α2-δ subunit of calcium channels, resulting in a reduction in the release of several&#xD;
      neurotransmitters including glutamate, noradrenaline, serotonin, dopamine and substance P.&#xD;
&#xD;
      Pregabalin could reduce the hyperexcitability of dorsal horn neurons induced by tissue&#xD;
      damage; therefore it may be useful in the postsurgical pain prevention.&#xD;
&#xD;
      In 2015, a meta-analysis published in British Medical Journal (BMJ) suggested that pregabalin&#xD;
      could improve postoperative analgesia and opioid-related adverse effects namely, vomiting and&#xD;
      visual disturbances after surgery. However, the use of the pregabalin for acute postoperative&#xD;
      pain is still under trial though widely reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be allocated randomly using computer generated randomization table into three equal groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>double-blinded ( patient and outcome assessors)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>changes in Postoperative pain</measure>
    <time_frame>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 hours postoperatively</time_frame>
    <description>will be assessed by visual analogue scale (VAS), On a scale of 0-10, the patient will learn to quantify postoperative pain where 0= No pain and 10= Maximum worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of sedation</measure>
    <time_frame>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 hours postoperatively</time_frame>
    <description>using the modified Ramsay Sedation Score:&#xD;
Patient is anxious and agitated or restless, or both.&#xD;
Patient is cooperative, oriented and tranquil.&#xD;
Patient responds to commands only.&#xD;
Patient exhibits brisk response to light glabellar tap or loud auditory stimulus.&#xD;
Patient exhibits sluggish response to light glabellar tap or loud auditory stimulus.&#xD;
Patient exhibits no response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of rescue analgesic</measure>
    <time_frame>in the first 24 hours</time_frame>
    <description>Total amount of rescue analgesic requirement by the patient</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Gynecologic Disease</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the patient will receive one placebo capsule (vitamin c) once one hour before the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Pregabalin 150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patient will receive one capsule of pregabalin 150 mg once one hour before the operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Pregabalin 300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patient will receive one capsule of pregabalin 300 mg once one hour before the operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo capsule (vitamin c)</intervention_name>
    <description>the patient will receive one placebo capsule (vitamin c) once one hour before the operation</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group pregabalin 150</intervention_name>
    <description>the patient will receive one capsule of pregabalin 150 mg once one hour before the operation</description>
    <arm_group_label>Group Pregabalin 150</arm_group_label>
    <other_name>p150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group pregabalin 300</intervention_name>
    <description>the patient will receive one capsule of pregabalin 300 mg once one hour before the operation</description>
    <arm_group_label>Group Pregabalin 300</arm_group_label>
    <other_name>p300</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physical status: ASA I-II&#xD;
&#xD;
          -  BMI ≥ 20kg/m2 &amp; ≤ 35kg/m2,&#xD;
&#xD;
          -  Written informed consent from the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known history of allergy to study drugs,&#xD;
&#xD;
          -  Patients on ACE inhibitors, anticonvulsant therapy or any drug interacting with&#xD;
             pregabalin,&#xD;
&#xD;
          -  Patients on chronic alcohol, opioid, tranquilizer or sedative use,&#xD;
&#xD;
          -  Patient with renal impairment or heart failure,&#xD;
&#xD;
          -  Pregnant females, Psychological, mental disorders or depression,&#xD;
&#xD;
          -  Patients receiving anticoagulants therapy or suspected coagulopathy,&#xD;
&#xD;
          -  Patients already on pregbalin or gabapentin therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients scheduled for benign gynecological surgeries (abdominal hysterectomy, myomectomy, adnexal mass or disturbed ectopic pregnancy) under spinal anesthesia.</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Asmaa M Galal, MD</last_name>
    <phone>01271550089</phone>
    <phone_ext>002</phone_ext>
    <email>asmaa_galal79@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rehab A Wahdan, MD</last_name>
    <phone>01003481323</phone>
    <phone_ext>002</phone_ext>
    <email>obz13w@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>faculty of medicine, Zagazig university</name>
      <address>
        <city>Zagazig</city>
        <state>Elsharqya</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howaida A Kamal, MD</last_name>
      <phone>01225096755</phone>
      <phone_ext>002</phone_ext>
      <email>k.howaida@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Guay DR. Pregabalin in neuropathic pain: a more &quot;pharmaceutically elegant&quot; gabapentin? Am J Geriatr Pharmacother. 2005 Dec;3(4):274-87. Review.</citation>
    <PMID>16503325</PMID>
  </reference>
  <reference>
    <citation>Dahl JB, Mathiesen O, Møiniche S. 'Protective premedication': an option with gabapentin and related drugs? A review of gabapentin and pregabalin in in the treatment of post-operative pain. Acta Anaesthesiol Scand. 2004 Oct;48(9):1130-6. Review.</citation>
    <PMID>15352959</PMID>
  </reference>
  <reference>
    <citation>Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2015 Jan;114(1):10-31. doi: 10.1093/bja/aeu293. Epub 2014 Sep 10. Review.</citation>
    <PMID>25209095</PMID>
  </reference>
  <reference>
    <citation>Balaban F, Yağar S, Özgök A, Koç M, Güllapoğlu H. A randomized, placebo-controlled study of pregabalin for postoperative pain intensity after laparoscopic cholecystectomy. J Clin Anesth. 2012 May;24(3):175-8. doi: 10.1016/j.jclinane.2011.06.027. Epub 2012 Mar 28.</citation>
    <PMID>22459341</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Asmaa Mohammed Galal El-Deen</investigator_full_name>
    <investigator_title>lecturer of anesthesia and surgical intensive care</investigator_title>
  </responsible_party>
  <keyword>Oral Pregabalin</keyword>
  <keyword>Postoperative Pain Relief</keyword>
  <keyword>Gynecological Surgeries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>planned after the completion of the study and publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>planned after the completion of the study and publication</ipd_time_frame>
    <ipd_access_criteria>principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

